Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Drug Testing and Analysis is Scopus-indexed (Q2, CiteScore 5.4), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by John Wiley and Sons Ltd.
Checked against the index lists dated .
ISSN 1942-7603Verify ISSN ↗1942-7611Verify ISSN ↗
Publisher: John Wiley and Sons Ltd
Cost to publish: About US$4,440 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmaceutical Science | 65 / 191 | 66th | Q2 |
| Spectroscopy | 30 / 81 | 63rd | Q2 |
| Analytical Chemistry | 61 / 160 | 62nd | Q2 |
| Environmental Chemistry | 73 / 157 | 53rd | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2009–present, best quartile Q2, CiteScore 5.4.
Drug Testing and Analysis is Q2 in Pharmaceutical Science (rank 65 of 191), Q2 in Spectroscopy (rank 30 of 81) and Q2 in Analytical Chemistry (rank 61 of 160), by CiteScore 2025. It is ranked in 4 subject areas in all.
Drug Testing and Analysis is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.4, which places it in quartile Q2 at the 66th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.712, quartile Q2, with an H-index of 74.
The publisher lists an article processing charge of about US$4,440 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Drug Testing and Analysis is published by John Wiley and Sons Ltd. Its print ISSN is 1942-7603 and its online ISSN is 1942-7611.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Drug Testing and Analysis has an h-index of 82 and a 2-year mean of 2.76 citations per paper (OpenAlex). Its Scopus CiteScore is 5.4, quartile Q2. On 2-year citations it ranks #69 of 177 Scopus journals in Pharmaceutical Science.
Drug Testing and Analysis published 170 papers in 2025; its busiest recent year was 2020 with 233. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 90 research articles (2026), authors are most often from Germany (14.8%), China (10.4%) and Italy (9.1%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 5 retracted papers are recorded (1.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.